CD86 and acute lymphoblastic leukemia: CD86 expression in MRD‐positive cases proved to be a useful MRD marker because it showed stable expression: in the majority of childhood B‐ALL cases (40/56, 71%), the CD86 expression was unchanged or increased on day 15 of treatment compared to diagnosis.56